Since the Spike of SARS‐CoV‐2 antagonizes RIG‐I signaling, interacts with IRF3 and further blocks IFN‐I activation and induction of downstream signaling, it may serve as a key target for therapeutic intervention in COVID‐19.130. Here, RIGI is linked to COVID-19.